Search results for "HIV"

showing 10 items of 1527 documents

Enhanced oxidative stress and increased mitochondrial mass during Efavirenz-induced apoptosis in human hepatic cells

2010

BACKGROUND AND PURPOSE Efavirenz (EFV) is widely used in the treatment of HIV-1 infection. Though highly efficient, there is growing concern about EFV-related side effects, the molecular basis of which remains elusive. EXPERIMENTAL APPROACH In vitro studies were performed to address the effect of clinically relevant concentrations of EFV (10, 25 and 50 mu M) on human hepatic cells. KEY RESULTS Cellular proliferation and viability were reduced in a concentration-dependent manner. Analyses of the cell cycle and several cell death parameters (chromatin condensation, phosphatidylserine exteriorization, mitochondrial proapoptotic protein translocation and caspase activation) revealed that EFV tr…

CyclopropanesMalehepatotoxicityCarcinoma HepatocellularTime FactorsAnti-HIV AgentsCell SurvivalApoptosisMitochondria LiverPhosphatidylserinesAntioxidantsSuperoxidesHumansChromansantiretroviral drugsCell Proliferationreactive oxygen speciesDose-Response Relationship DrugCell CycleLiver NeoplasmsChromatin Assembly and DisassemblyResearch PapersGlutathioneBenzoxazinesmitochondriaOxidative Stressside effectscell deathLiverAlkynesFemaleEfavirenzApoptosis Regulatory ProteinsHeLa Cells
researchProduct

Pharmacokinetic interaction between efavirenz and ketoconazole in rats

2009

It is well known that efavirenz and ketoconazole act as an inducer and inhibitor of CYP3A4, respectively. As a result of these actions, co-administration of these drugs may result in changes in the pharmacoki- netic parameters of one or both of them. 2. Duodenum-cannulated rats have been used to compare the effect of intraduodenal (KC i.d. ) and intrave- nous administration of ketoconazole (KC i.v. ) on the pharmacokinetics of efavirenz after intraduodenal administration, as well as the potential effect of efavirenz as a CYP450 inducer on ketoconazole phar - macokinetic profile. 3. While KC i.v. did not show any significant effect on efavirenz pharmacokinetic profile, KC i.d. increased sig-…

CyclopropanesMalemedicine.medical_specialtyAntifungal AgentsEfavirenzAnti-HIV AgentsHealth Toxicology and MutagenesisPharmacologyToxicologyBiochemistryEnteral administrationDrug Administration SchedulePeak concentrationchemistry.chemical_compoundCytochrome P-450 Enzyme SystemPharmacokineticsimmune system diseasesInternal medicinemedicineAnimalsCytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsDrug InteractionsInducerRats WistarPharmacologyCYP3A4Chemistryvirus diseasesGeneral MedicineBenzoxazinesRatsKetoconazoleEndocrinologyAlkynesKetoconazolePharmacokinetic interactionmedicine.drugXenobiotica
researchProduct

Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations.

2015

ABSTRACT Between 22 and 45% of HIV-positive subjects are likely to report symptoms of depression. Considering this background, a potential pharmacokinetic interaction between the nonnucleoside reverse transcriptase inhibitor efavirenz (EFV) and two antidepressants, sertraline (SRT) and nortriptyline (NT), was studied. Rats were administered EFV alone or together with the antidepressants, and changes in the plasma levels and pharmacokinetic parameters of EFV were analyzed. Additional in vitro experiments with rat and human hepatic microsomes were carried out to evaluate the inhibitory effect of SRT and NT on EFV metabolism by determining the formation rate of the major EFV metabolite (8-OH-E…

CyclopropanesMalemedicine.medical_specialtyEfavirenzAnti-HIV AgentsMetaboliteNortriptylinePharmacology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsIn vivoInternal medicineSertralinemedicineAnimalsHumansPharmacology (medical)Drug Interactions030212 general & internal medicineRats WistarIC50PharmacologyChemistryAntidepressive AgentsBenzoxazinesInfectious DiseasesEndocrinologyAlkynesMicrosomeMicrosomes LiverReverse Transcriptase InhibitorsNortriptylinehuman activitiesDrug metabolismmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Involvement of nitric oxide in the mitochondrial action of efavirenz: a differential effect on neurons and glial cells

2014

Abstract The anti-human immunodeficiency virus (HIV) drug efavirenz (EFV) alters mitochondrial function in cultured neurons and glial cells. Nitric oxide (NO) is a mediator of mitochondrial dysfunction associated with HIV central nervous system symptoms. We show that EFV promotes inducible nitric oxide synthase (iNOS) expression in cultured glial cells and generated NO undermines their mitochondrial function, as inhibition of NOS partially reverses this effect. EFV inhibits mitochondrial Complex I in both neurons and glia; however, when the latter cells are treated for longer periods, other mitochondrial complexes are also affected in accordance with the increased NO production. These findi…

CyclopropanesNNRTIEfavirenzAnti-HIV AgentsCentral nervous systemNitric Oxide Synthase Type IIMitochondrionBiologyNitric OxideNitric oxideCell Linechemistry.chemical_compoundMediatornitric oxidemedicineImmunology and AllergyHumansNeuronsNeurotoxicityelectron transport chainHIVefavirenzmedicine.diseasecentral nervous systemCell biologyBenzoxazinesMitochondriaNitric oxide synthasemitochondriaInfectious Diseasesmedicine.anatomical_structurechemistryAlkynesImmunologybiology.proteinNeurogliaNeuroglia
researchProduct

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir i…

2013

Objectives: To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients. Patients and methods: A retrospective, longitudinal, multicentre analysis of adult patients enrolled in the Antiretroviral Resistance Cohort Analysis (ARCA), a national prospective observational cohort of HIV-1-infected patients followed up at more than 100 clinical and laboratory units in Italy. Patients eligible were those starting first-line antiretroviral therapy between 1 June 2004 and 15 April 2011 and who were followed up for at least 6 months. The primary endpoint was durability, define…

CyclopropanesTime FactorsPyridinesPyridineDrug ResistanceLopinavir/ritonavirLongitudinal StudieHIV InfectionsPharmacologyAntiviral therapyDeoxycytidineLopinavirCohort Studieschemistry.chemical_compoundimmune system diseasesRetrospective StudieOrganophosphonateMedicineEmtricitabineHIV InfectionPharmacology (medical)ViralLongitudinal StudiesProspective StudiesProspective cohort studyvirus diseasesLopinavirInfectious DiseasesAnti-Retroviral AgentsItalyAlkynesCombinationOligopeptideHIV/AIDSDrug Therapy CombinationOligopeptidesmedicine.drugHumanMicrobiology (medical)Benzoxazinemedicine.medical_specialtyEfavirenzTime Factorantiretroviral therapyAtazanavir SulfateOrganophosphonatesfirst-line therapy tenofovir emtricitabine atazanavir/ritonavirSettore MED/17 - MALATTIE INFETTIVEEmtricitabineDurabilityDrug TherapyInternal medicineDrug Resistance ViralDrug utilizationHumansAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Time Factors; Pharmacology; Pharmacology (medical); Infectious DiseasesTenofovirRetrospective StudiesAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time FactorsPharmacologyRitonavirbusiness.industryAdenineAtazanavirBenzoxazinesRegimenProspective StudiechemistryHIV-1RitonavirAnti-Retroviral AgentCohort StudieTenofovir/emtricitabinebusiness
researchProduct

Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir.

2021

Integrase inhibitors appear to increase body weight, but paradoxically some data indicate that raltegravir (RAL) may decrease liver fat. Our objective was to study the effects of switching from a protease inhibitor (PI) or efavirenz (EFV) to RAL on liver fat, body composition, and metabolic parameters among people living with HIV (PLWH) with high risk for nonalcoholic fatty liver disease (NAFLD). We randomized overweight PLWH with signs of metabolic syndrome to switch a PI or EFV to RAL (

Cyclopropanesmedicine.medical_specialtyanimal structuresEfavirenzIntegrase inhibitorAdipose tissueHIV Infections03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAdipocyteInternal medicineRaltegravir PotassiumNonalcoholic fatty liver diseasemedicineHumansProtease inhibitor (pharmacology)Protease Inhibitors030212 general & internal medicinebusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseaseRaltegravir3. Good healthBenzoxazinesInfectious DiseasesEndocrinologychemistryAdipose TissueLiverAlkynesBody Composition030211 gastroenterology & hepatologymedicine.symptombusinessWeight gainmedicine.drugAIDS patient care and STDs
researchProduct

Alteration of nuclear (2'-5')oligoriboadenylate synthetase and nuclease activities preceding replication of human immunodeficiency virus in H9 cells.

1988

After infection of the respective target cells with the human immunodeficiency virus (HIV-1) viral progeny is produced only after a short temporary delay of some days, depending on cell type. After this period of time a sudden onset of HIV-1 protein synthesis with a dramatic increase in virus release occurs. (2'-5')Oligoriboadenylates [(2'-5')A], capable to activate a latent ribonuclease (RNase L) degrading both mRNA and rRNA, are known mediators involved in the early response of cells to virus infection. Here we show that the (2'-5')A-synthesizing (2'-5')A synthetase, which is inducible by interferon and activated by double-stranded RNA, as well as a (2'-5')A nuclease (2',3'-exoribonucleas…

DNA ReplicationRNase PNuclear EnvelopeVirus ReplicationBiochemistryVirusCell LineSubstrate SpecificityInterferonExoribonucleaseEndoribonucleasesmedicine2'5'-Oligoadenylate SynthetaseHumansRibonucleaseCell NucleusMessenger RNAbiologyChemistryNucleic Acid HybridizationCell Transformation ViralVirologyMolecular biologyVirus ReleaseKineticsbiology.proteinHIV-1Exoribonuclease activitymedicine.drugBiological chemistry Hoppe-Seyler
researchProduct

Effects of HIV, antiretroviral therapy and prebiotics on the active fraction of the gut microbiota

2018

In a recent blinded randomized study, we found that in HIV-infected individuals a short supplementation with prebiotics (scGOS/lcFOS/glutamine) ameliorates dysbiosis of total gut bacteria, particularly among viremic untreated patients. Our study goal was to determine the fraction of the microbiota that becomes active during the intervention and that could provide additional functional information.A total of six healthy individuals, and 16 HIV-infected patients comprising viremic untreated patients (n = 5) and antiretroviral therapy-treated patients that are further divided into immunological responders (n = 7) and immunological nonresponders (n = 4) completed the 6-week course of prebiotic …

DNA Bacterial0301 basic medicine030106 microbiologyImmunologyHuman immunodeficiency virus (HIV)HIV InfectionsGut floramedicine.disease_causeDNA Ribosomallaw.inventionPlacebos03 medical and health sciencesPharmacotherapyImmune systemRandomized controlled triallawRNA Ribosomal 16SmedicineCluster AnalysisHumansImmunology and AllergyPhylogenyBacteriabiologybusiness.industrySequence Analysis DNAMiddle Agedmedicine.diseasebiology.organism_classificationAntiretroviral therapyGastrointestinal MicrobiomeGlutaminePrebiotics030104 developmental biologyInfectious DiseasesAnti-Retroviral AgentsImmunologybusinessDysbiosisFollow-Up StudiesAIDS
researchProduct

Capitanes del Renacimiento. Ética militar en la España mediterránea, c. 1500-1550

2004

En la Europa del siglo XVI los valores caballerescos, fundamento de la ética de la aristocracia militar, se enriquecieron con los ideales cortesanos. En este artículo estudiamos la difusión de esos ideales entre los oficiales del ejército de la Monarquía hispánica en los diversos reinos de la España Mediterránea. Estimamos que esta conjunción de principios morales proporcionó la base para una incipiente disciplina de los mandos militares. In Sixteenth Century Europe, the chivalric values which were in the core of military aristocracy ethics became enriched with court-like ideals. In this paper we study the diffusion of those ideals among army officers of the Hispanic Monarchy in the various…

DP1-402Ética militarEspañaReligious studies16th centuryHistory of SpainChivalryGenealogySiglo XVICourtDisciplineModern history 1453-KingdomMilitary ethicsGeographyD204-475MonarchySpainArmyCaballeríaEjércitoCorteDisciplinaHumanitiesAristocracy
researchProduct

Establishing a Digital Repository

2018

A short, non technical guide for establishing a digital repository.

DSpaceDigital Archive
researchProduct